First financial round – oversubscribed rights issue

Attgeno completes a first rights issue of 30 million SEK and previous loans are converted to new shares. The Attgeno board of directors is renewed to strengthen competence regarding business and pharmaceutical development. 

In autumn 2018, the Supernitro project was granted 5 million SEK in support from SweLife, (Swedish government research fund).